Further larger scale studies of schistosomal hepatic fibrosis and other causes ofliver fibrosis are required to validate the efficacy of peripheral CB1 receptorantagonists in reversing liver fibrosis. This evidence concerns the gene CNR1 and Hepatic fibrosis.